The clinical utility of Ki‐67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoids

Undergoing Long Term Therapy With Octreotide LAR Saju Joseph MD1, Erika Lindholm MD1 , Gang Li, PhD2, Ying Zhou, MS2, Vay Liang W. Go, MD3, Aaron I. Vinik, MD, PhD4, Thomas M. O’Dorisio, MD5, and Gregg Mamikunian, MS6, and Eugene A. Woltering MD, FACS1 1Department of Surgery, Sections of Surgical Endocrinology and Hepato-Biliary Surgery, Louisiana State University Health Sciences Center, New Orleans, LA; 2Department of Biostatistics, University of California, Los Angeles, CA; 3Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA; 4Streletz Diabetes Institute, East Virginia Medical School, Norfolk, VA; 5Division of Endocrinology & Metabolism, University of Iowa, Iowa City, IO, 6Inter Science Institute, Inglewood, CA